ACR CONVERGENCE 2021—Rheumatologists are often left in a challenging space when managing medications for patients with rheumatic diseases in relation to contraception, pregnancy and breastfeeding, especially with many novel immunosuppressants and often a dearth of pregnancy safety data. On Nov. 6 during ACR Convergence 2021, leading reproductive health experts came together to speak on this…
Andy Abril, MD, a lead author of the ACR/VF guideline for Takayasu arteritis (TAK), discusses the recommendations for TAK.
We are now a year-and-a-half into the COVID‑19 pandemic, and rheumatologists and rheumatology professionals are still facing some of the same challenges that began in spring 2020, as well as new ones. Most recently, we learned that COVID‑19 vaccine efficacy is reduced in some patients on immunosuppressive therapies and the need for additional immunization is…
Data from a single-center registry shines light on 20 years of trends in first-line, biologic disease-modifying anti-rheumatic drug prescriptions for patients with rheumatoid arthritis.
On May 6, the U.S. Food & Drug Administration’s (FDA’s) Arthritis Advisory Committee narrowly voted in support of avacopan, a C5a receptor inhibitor, for the treatment of adult patients with anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis. Although the panelists were excited about the possibility of a steroid-sparing therapy, some raised questions about whether results from…
JIA can manifest in a variety of ways. Experts discuss the implications of uveitis, systemic disease and lung involvement in sJIA.
Vision loss, implications of treatment and more—Sarah Mackie, BMBCh, PhD, MRCP, discussed the latest research on the evaluation and management of giant cell arteritis.
NEW YORK (Reuters Health)—Rituximab seemed to be a safe and effective treatment for systemic sclerosis (SSc) in a placebo-controlled validation trial in Japan.1 “A number of studies have examined B-cell depletion therapy for systemic sclerosis, and many of them have suggested that [this] is effective in treating systemic sclerosis,” Ayumi Yoshizaki, MD, tells Reuters Health…
The ACR, in concert with the Vasculitis Foundation, released three new vasculitis guidelines online first in July, with a fourth slated for publication by the end of the year. These are the first ever to be produced and endorsed by the ACR and the Vasculitis Foundation. Although most of the recommendations are conditional, due to…
A recent study of data from the FDA’s Adverse Event Reporting System reveals that 14 drugs commonly prescribed by rheumatologists are on the list of the top 50 drugs that can cause anaphylaxis.